This article is intended for hematologists/oncologists, gastroenterologists, internists, obstetricians/gynecologists/ women's health practitioners, nurses, surgeons, and other members of the healthcare team who treat and manage people of reproductive age who have cancer.
The goal of this activity is to provide medical news to primary care clinicians and other healthcare professionals in order to enhance patient care.
Upon completion of this activity, participants will be able to:
As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.
Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.
This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.
Medscape, LLC designates this enduring material for a maximum of 0.25
AMA PRA Category 1 Credit(s)™
. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Awarded 0.25 contact hour(s) of continuing nursing education for RNs and APNs; none of these credits is in the area of pharmacology.
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability
and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the
activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.
Follow these steps to earn CME/CE credit*:
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it.
Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print
out the tally as well as the certificates from the CME/CE Tracker.
*The credit that you receive is based on your user profile.
CME / ABIM MOC / CE Released: 10/30/2020
Valid for credit through: 10/30/2021
processing....
As cancer survival increases, quality of life, including fertility preservation, is an increasing concern for patients. Chemotherapy and radiotherapy are both effective cancer treatments but have persistent adverse effects on the reproductive system in both sexes.
For patients of reproductive age with newly diagnosed cancer, the opportunity to discuss fertility preservation is therefore crucial before starting chemotherapy or other treatment, as recommended by the American Society for Reproductive Medicine and the American Society of Clinical Oncology (ASCO). The goal of this cross-sectional study using survey data from the ASCO Quality Oncology Practice Initiative was to identify factors associated with fertility preservation counseling and referrals to reproductive specialists among patients of reproductive age before starting chemotherapy.
Less than half of patients with cancer who are of reproductive age receive fertility counseling, despite guidelines recommending that these discussions be had with every eligible patient.
The findings come from the largest study on this subject to date. Researchers surveyed nearly 7000 patients with cancer who were reproductive age. The study was published online July 17 in JAMA Network Open.
Only 44% of patients with cancer reported having had a discussion with their clinician about the risk for infertility associated with chemotherapy, the study found. Clinicians were more likely to discuss the risk for infertility with female patients than male patients, as well as with younger patients.
One reason these discussions are not being held is because of time constraints, commented lead author Ranjith Ramasamy, MD, director of male reproductive medicine and surgery and an associate professor in the Department of Urology at the University of Miami, Florida.
"There is so much to discuss when a patient is first diagnosed with cancer," he told Medscape Medical News. "The patient wants to know about the treatment -- the different options, the side effects, prognosis, insurance coverage -- and fertility preservations gets pushed to the wayside.
"Providers often do not have the time or the resources to have these discussions, and the best solution is to make a referral to a specialist," said Dr Ramasamy. "It's not a big issue to do this, and the office staff can all play a very important role in arranging a referral."
He added that at his institution, making a referral for fertility preservation comes up as a best practice alert through the electronic medical records system.
Dr Ramasamy emphasized the importance of bringing up this topic, especially with younger patients. "About 75% to 80% of adolescents diagnosed with cancer are surviving, and it is incumbent upon doctors that we think about the future," said Dr Ramasamy. "Even if they're not thinking about it now, they may want a family in the future."
For several reasons, fertility is often overlooked by patients and physicians when cancer is first diagnosed, but as survival increases, so does the importance of future quality of life. The American Society for Reproductive Medicine and ASCO both recommend that clinicians discuss fertility preservation with adult and pediatric patients before the initiation of anticancer therapy.
Less Counseling for Men and for Older Patients
For their study, Dr Ramasamy and colleagues used data obtained from the ASCO Quality Oncology Practice Initiative. They identified 6976 patients as being of reproductive age, ranging from 18 to 40 years for women (n = 3405) and from 18 to 50 years for men (n = 3571).
Within this group, 3036 patients (44%) received counseling about the risk for infertility that was associated with their treatment. Women were more likely to be counseled (56%) than men (32%; P<.001).
Younger patients were more likely to be counseled. The frequency of discussions concerning infertility risk declined as the patient age increased (odds ratio [OR], 0.91; P<.001). Race/ethnicity did not appear to have an effect on the frequency of discussions (Black: OR, 1.03; Asian: OR, 1.14; Hispanic: OR, 1.04; other or not reported: OR, 0.99).
Overall, factors that were associated with a lower likelihood of having this discussion included male sex (OR, 0.73), increasing age (OR, 0.93), private practice setting (OR, 0.70), and a lack of a multidisciplinary team (OR, 0.54). Factors that were associated with a higher likelihood of discussion included having breast cancer (OR, 1.39) and lymphatic or hematopoietic cancers (OR, 1.79), treatment in an academic setting (OR, 1.45), and the practice's offering clinical trial enrollment (OR, 1.60).
Insurance may not cover the cost of fertility preservation, which may present a barrier for many patients. As of 2019, 5 states had passed laws that mandate coverage. In those states, patients were more often counseled or referred to a fertility specialist after the laws went into effect.
Barriers to Referral
Approached by Medscape Medical News for an independent comment, Maryam B. Lustberg, MD, MPH, associate professor of medicine and medical director of cancer support services, the Ohio State Comprehensive Cancer Center, Columbus, believes that these conversations are not happening for a number of reasons. These include a lack of time, a lack of awareness, competing priorities because of the need to treat an aggressive cancer quickly, assumptions as to what patients want and need and a failure to engage in shared decision making, and a lack of resources and access to fertility preservation counseling and services.
"A new diagnosis requires a lot of discussion points, and both patients and providers can feel overwhelmed to cover and take in all of these points," said Dr Lustberg. "If fertility is mentioned quickly in passing, the patient and family may not have time to process the information and may initially say they are not interested."
Another reason is that some oncologists may not be as aware of guidelines or assume some patients may not be able to afford the services or want the services. "Disparities in care due to socioeconomic and race are also a consideration," she said. "Additionally, some oncologists may make assumptions that patients with advanced cancers may not want to discuss this issue and therefore not bring it up."
Dr Lustberg also pointed out that there are some barriers to making referrals. "Navigators in young adult care and fertility preservation are definitely helpful and increase referrals, but not all oncology practices may have access to these," she said. "Virtually delivering counseling services to practices that may not have this will be helpful, and we are working toward implementing this type of services."
This study was funded by the Department of Urology, University of Miami Miller School of Medicine. The authors have disclosed no relevant financial relationships. Dr Lustberg has relationships with PledPharma, Disarm Therapeutics, and Hologic/Cynosure.
JAMA Netw Open. Published online July 17, 2020.[1]